½ðºÌÓéÀÖ³Ç

In application of article 8:6 of the Royal Decree executing the new Belgian Code of Companies and Associations, ½ðºÌÓéÀÖ³Ç SA/NV announces that following exercises of stock options by its employees, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of shares to the relevant employees, within the framework of the Long Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

<img width="922" src="_up/ucb_com_presscenter/images/200214-disposal-of-own-shares-2.png">

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

Isabelle Ghellynck,
Investor Relations, ½ðºÌÓéÀÖ³Ç
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news